Incyte Corporation (INCY)
Debt-to-capital ratio
Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long-term debt | US$ in thousands | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 18,080 | 17,862 | 17,647 |
Total stockholders’ equity | US$ in thousands | 5,189,840 | 4,931,450 | 4,740,690 | 4,462,570 | 4,370,120 | 4,226,650 | 4,085,060 | 3,863,070 | 3,770,000 | 3,148,660 | 2,935,860 | 2,727,840 | 2,611,270 | 2,390,830 | 2,344,600 | 1,937,720 | 2,598,410 | 2,422,530 | 2,247,190 | 2,085,570 |
Debt-to-capital ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 |
December 31, 2023 calculation
Debt-to-capital ratio = Long-term debt ÷ (Long-term debt + Total stockholders’ equity)
= $—K ÷ ($—K + $5,189,840K)
= 0.00
The debt-to-capital ratio of Incyte Corp. has remained consistent at 0.01 for each quarter from Q1 2022 to Q4 2023. This indicates that the company has a very low level of debt relative to its total capital, with only 1% of its capital structure being funded by debt. A low debt-to-capital ratio suggests that the company has a strong financial position, as it relies more on equity financing rather than debt financing. This can be considered a positive indicator of financial stability and creditworthiness for Incyte Corp.
Peer comparison
Dec 31, 2023
Company name
Symbol
Debt-to-capital ratio
Incyte Corporation
INCY
0.00
Arrowhead Pharmaceuticals Inc
ARWR
0.00
Charles River Laboratories
CRL
0.00
Exelixis Inc
EXEL
0.00
IQVIA Holdings Inc
IQV
0.68
Medpace Holdings Inc
MEDP
0.00